Abstract
Senescence is defined as an irreversible growth arrest that is characterised by a changed morphology, gene expression pattern and chromatin structure as well as an activated DNA damage response. Senescence has a dual role for tumour development. Firstly, it acts as a tumour suppressor to prevent the proliferation of seriously damaged cells. Important mechanisms ensuring the stop of genomically altered cells to proliferate are the activation of ATM, p53 and the DNA damage response (DDR). In addition it emerges in recent years that oncogene activation acts as a genetic stress and induces senescence as well using similar downstream components: DNA damage activation, changes in gene expression and chromatin structure. Therefore, senescence functions as a powerful tumour suppressor that protects cells expressing activated oncogenes in vivo from becoming neoplastic and malignant. The fact, that oncogene induced senescent cells were mainly found in early, pre-malignant tumour stages suggest that this senescent state has to be overcome during tumourigenesis in order for a tumour to progress to malignancy. At the same time cellular senescence is increasingly recognised as a possible outcome for the treatment of human tumours because it is executed by cells in response to therapeutic treatments, such as drugs and irradiation. While historically apoptosis was considered the only desirable outcome of any anti-neoplastic treatment it emerges recently that senescence could be a potential alternative outcome for tumour therapy in vivo. Animal and tissue culture models have been developed over the last years shedding more light on this novel field of cancer treatment. Whether senescence induction is an advantage or a backdrop for tumour treatment has still to be elucidated since experimental proof in human tumour models is still in an infant stage. This review focuses on the basic mechanisms and recent advances for the induction of senescence as a potential outcome of cancer therapy and discusses the potential for a clinical application.
Keywords: Cancer, senescence, stress, tumour therapy, DNA damage response, oncogene-induced senescence
Current Pharmaceutical Design
Title: Cellular Senescence in the Development and Treatment of Cancer
Volume: 16 Issue: 1
Author(s): Gabriele Saretzki
Affiliation:
Keywords: Cancer, senescence, stress, tumour therapy, DNA damage response, oncogene-induced senescence
Abstract: Senescence is defined as an irreversible growth arrest that is characterised by a changed morphology, gene expression pattern and chromatin structure as well as an activated DNA damage response. Senescence has a dual role for tumour development. Firstly, it acts as a tumour suppressor to prevent the proliferation of seriously damaged cells. Important mechanisms ensuring the stop of genomically altered cells to proliferate are the activation of ATM, p53 and the DNA damage response (DDR). In addition it emerges in recent years that oncogene activation acts as a genetic stress and induces senescence as well using similar downstream components: DNA damage activation, changes in gene expression and chromatin structure. Therefore, senescence functions as a powerful tumour suppressor that protects cells expressing activated oncogenes in vivo from becoming neoplastic and malignant. The fact, that oncogene induced senescent cells were mainly found in early, pre-malignant tumour stages suggest that this senescent state has to be overcome during tumourigenesis in order for a tumour to progress to malignancy. At the same time cellular senescence is increasingly recognised as a possible outcome for the treatment of human tumours because it is executed by cells in response to therapeutic treatments, such as drugs and irradiation. While historically apoptosis was considered the only desirable outcome of any anti-neoplastic treatment it emerges recently that senescence could be a potential alternative outcome for tumour therapy in vivo. Animal and tissue culture models have been developed over the last years shedding more light on this novel field of cancer treatment. Whether senescence induction is an advantage or a backdrop for tumour treatment has still to be elucidated since experimental proof in human tumour models is still in an infant stage. This review focuses on the basic mechanisms and recent advances for the induction of senescence as a potential outcome of cancer therapy and discusses the potential for a clinical application.
Export Options
About this article
Cite this article as:
Saretzki Gabriele, Cellular Senescence in the Development and Treatment of Cancer, Current Pharmaceutical Design 2010; 16 (1) . https://dx.doi.org/10.2174/138161210789941874
| DOI https://dx.doi.org/10.2174/138161210789941874 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc., has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Accelerating Cancer drug discovery using Artificial intelligence and In Silico methods
The Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Anti-Cancer Agents in Medicinal Chemistry Curcumin Combats against Organophosphate Pesticides Toxicity: A Review of the Current Evidence and Molecular Pathways
Current Medicinal Chemistry Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Therapeutic Potential of Natural Compounds that Regulate the Activity of Protein Kinase C
Current Medicinal Chemistry Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer
Current Medical Imaging Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug
Current Protein & Peptide Science Exploring Optic Nerve Axon Regeneration
Current Neuropharmacology Proline-Directed Protein Kinase FA as a Potential Target for Diagnosis and Therapy of Human Cancers
Current Cancer Drug Targets Chemical Composition and Biological Activity of Essential Oils of Cumin and Coriander Fruits from Egypt
The Natural Products Journal Hyaluronan-based Multifunctional Nano-carriers for Combination Cancer Therapy
Current Topics in Medicinal Chemistry Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study
Current HIV Research Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Nanoparticulate Drug Delivery Sytem for Cancer Therapy: Oppourtunities and Challenges
Recent Patents on Nanomedicine





